165 related articles for article (PubMed ID: 35778826)
21. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
22. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
23. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer.
Matsuo K; Nusbaum DJ; Matsuzaki S; Chang EJ; Roman LD; Wright JD; Harter P; Klar M
Gynecol Oncol; 2020 Oct; 159(1):43-51. PubMed ID: 32690393
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
[TBL] [Abstract][Full Text] [Related]
25. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey.
Lajer H; Elnegaard S; Christensen RD; Ortoft G; Schledermann DE; Mogensen O
Acta Obstet Gynecol Scand; 2012 Aug; 91(8):976-82. PubMed ID: 22548255
[TBL] [Abstract][Full Text] [Related]
26. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Mar; 152(3):599-604. PubMed ID: 30551884
[TBL] [Abstract][Full Text] [Related]
27. Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee.
Shigeta S; Nagase S; Mikami M; Ikeda M; Shida M; Sakaguchi I; Ushioda N; Takahashi F; Yamagami W; Yaegashi N; Udagawa Y; Katabuchi H
J Gynecol Oncol; 2017 Nov; 28(6):e76. PubMed ID: 29027394
[TBL] [Abstract][Full Text] [Related]
28. The nature of early-stage endometrial cancer recurrence-A national cohort study.
Jeppesen MM; Jensen PT; Gilså Hansen D; Iachina M; Mogensen O
Eur J Cancer; 2016 Dec; 69():51-60. PubMed ID: 27816832
[TBL] [Abstract][Full Text] [Related]
29. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
[TBL] [Abstract][Full Text] [Related]
30. Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center.
Tai YJ; Hsu HC; Chiang YC; Chen YL; Chen CA; Cheng WF
Int J Environ Res Public Health; 2019 Jul; 16(14):. PubMed ID: 31323767
[TBL] [Abstract][Full Text] [Related]
31. Grade 1 Endometrioid Carcinoma With an Area of Serous Carcinoma Less than 5% Is More Aggressive than Stage IA Pure-type Grade 1 Endometrioid Carcinoma.
Miyamoto M; Tsuda H; Sugiura A; Kita T; Kataoka Y; Ishii K; Kudo K; Matsuura H; Ishibashi H; Iwahashi H; Hada T; Suzuki R; Takano M
In Vivo; 2021; 35(2):1205-1209. PubMed ID: 33622922
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of high-grade endometrial cancer: a comparison of serous-type and clear cell type to grade 3 endometrioid-type.
Goto T; Takano M; Aoyama T; Miyamoto M; Watanabe A; Kato M; Sasaki N; Hirata J; Sasa H; Furuya K
Eur J Gynaecol Oncol; 2012; 33(6):579-83. PubMed ID: 23327049
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
34. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.
Hamilton CA; Cheung MK; Osann K; Chen L; Teng NN; Longacre TA; Powell MA; Hendrickson MR; Kapp DS; Chan JK
Br J Cancer; 2006 Mar; 94(5):642-6. PubMed ID: 16495918
[TBL] [Abstract][Full Text] [Related]
35. Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group study.
Gemer O; Segev Y; Helpman L; Hag-Yahia N; Eitan R; Raban O; Vaknin Z; Leytes S; Ben Arie A; Amit A; Levy T; Namazov A; Volodarsky M; Ben Shachar I; Atlas I; Bruchim I; Lavie O
Am J Obstet Gynecol; 2018 Aug; 219(2):181.e1-181.e6. PubMed ID: 29792852
[TBL] [Abstract][Full Text] [Related]
36. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery.
Li S; Zhu Z
J Ovarian Res; 2020 Aug; 13(1):91. PubMed ID: 32772926
[TBL] [Abstract][Full Text] [Related]
38. Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy.
Reshko LB; Gaskins JT; Dryden SM; Metzinger DS; Todd SL; Eldredge-Hindy HB; Silva SR
Int J Gynecol Cancer; 2021 May; 31(5):694-701. PubMed ID: 33741653
[TBL] [Abstract][Full Text] [Related]
39. Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer.
Nakayama K; Nagai Y; Ishikawa M; Aoki Y; Miyazaki K
Int J Clin Oncol; 2010 Oct; 15(5):440-6. PubMed ID: 20419386
[TBL] [Abstract][Full Text] [Related]
40. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival.
Bristow RE; Zahurak ML; Alexander CJ; Zellars RC; Montz FJ
Int J Gynecol Cancer; 2003; 13(5):664-72. PubMed ID: 14675352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
